WO2009105792A1 - Nanoparticle carriers for drug administration and process for producing same - Google Patents

Nanoparticle carriers for drug administration and process for producing same Download PDF

Info

Publication number
WO2009105792A1
WO2009105792A1 PCT/ZA2008/000012 ZA2008000012W WO2009105792A1 WO 2009105792 A1 WO2009105792 A1 WO 2009105792A1 ZA 2008000012 W ZA2008000012 W ZA 2008000012W WO 2009105792 A1 WO2009105792 A1 WO 2009105792A1
Authority
WO
WIPO (PCT)
Prior art keywords
phase
oil
water
emulsion
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ZA2008/000012
Other languages
French (fr)
Inventor
Lonji Kalombo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council for Scientific and Industrial Research CSIR
Original Assignee
Council for Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AP2010005389A priority Critical patent/AP2966A/en
Priority to HK10112296.4A priority patent/HK1145973B/en
Priority to AU2008351331A priority patent/AU2008351331B2/en
Priority to JP2010547882A priority patent/JP5575667B2/en
Priority to CA2714429A priority patent/CA2714429C/en
Priority to ES201090058A priority patent/ES2397016B1/en
Priority to CN2008801270301A priority patent/CN101951895B/en
Priority to MX2010008902A priority patent/MX2010008902A/en
Priority to EP08733215A priority patent/EP2249817B8/en
Application filed by Council for Scientific and Industrial Research CSIR filed Critical Council for Scientific and Industrial Research CSIR
Priority to AT08733215T priority patent/ATE537817T1/en
Priority to PCT/ZA2008/000012 priority patent/WO2009105792A1/en
Priority to DE112008003727T priority patent/DE112008003727T5/en
Priority to GB1013546.5A priority patent/GB2469965B/en
Publication of WO2009105792A1 publication Critical patent/WO2009105792A1/en
Priority to US12/858,074 priority patent/US8518450B2/en
Anticipated expiration legal-status Critical
Priority to ZA2010/06639A priority patent/ZA201006639B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the invention relates to nanoparticle carriers for oral administration of medically active compounds and/or other compounds.
  • the spray-drying technique has seen wide application in the preparation of pharmaceutical powders, mostly for pulmonary drug delivery, with specific characteristics such as particle size, density and shape. It is a well-established method for producing solid powder by atomising suspensions or solutions into droplets followed by a drying process in flowing hot air.
  • spray-drying can also be used as an encapsulation method where active substances are entrapped in a polymeric matrix or shell. It is reported that several colloidal systems such as emulsions or liposomes were successfully spray dried with preservation of their structure using drying-aid agents, particularly sugars such as lactose, sorbitol and trehalose.
  • One of the merits of the spray-drying technique is that it is a cost effective and quick drying process applicable to a broad range of pharmaceutical products and leading to the production of a free flowing powder, characterized by very low water content, preventing therefore the degradation of the active. This is meaningful for the development of long-term stable carriers, mostly when these carriers are in the range of nano scale, designed specifically for the delivery of active compounds at the site of interest.
  • the spray drying technique can produce nano scale solid particles and solid lipid nanoparticles loaded with active agents to be used as delivery systems for pulmonary airways. It is worthwhile to note that in most cases where this technique was applied to produce solid nanoparticles, it was, in fact, a drying process of nanocapsules obtained by other techniques. Thereafter the suspension of the nanoparticles was subjected to spray drying. This resulted often in the production of particles with very broad size range from nano to micron size, despite the presence of disaccharides as drying excipients in the formulation.
  • the invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by:
  • the nanoparticles thus produced may be multifunctional nanoparticles.
  • the carbohydrate may be a saccharide.
  • the saccharide may be a disaccharide.
  • the disaccharide may be lactose, maltose, isomaltose, mannobiose, trehalose, cellobiose, or the like.
  • the saccharide may be combined with a cationic biodegradable muco-adhesive polysaccharide.
  • the polysaccharide may be chitosan or derivatives thereof.
  • the oil-phase of the emulsion may be doped with a surfactant.
  • the water-phase of the emulsion may be doped with surfactant.
  • the surfactant may be a nonionic surfactant.
  • the surfactant may be based on acetylenic diol chemistry.
  • the surfactant may be a polymeric nonionic surfactant.
  • the polymeric nonionic surfactant in the water-phase may be polyvinyl alcohol (PVA), partially hydrolysed.
  • PVA polyvinyl alcohol
  • the polymer may be in the oil-phase of the emulsion.
  • the polymer in the oil-phase may be PLGA (poly(lactic-co-glycolic acid)).
  • Both oil-phase and water-phase polymers may be present.
  • the drug may be added to the oil-phase.
  • the drug may be a hydrophilic drug which is added to the internal water-phase.
  • the drug may be hydrophobic and may optionally be added to the oil phase.
  • the drug may be Rifampicin, Isoniazid, Ethambutol, or Pyrazynamide.
  • the outer water-phase of the emulsion may include polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the oil-phase may include stearic acid.
  • the nanoparticles thus formed may be substantially spherical.
  • the particle size distribution of the nanoparticles may be from 180 nm to 250 nm diameter.
  • anti-tuberculosis antibiotics including isoniazid (INH) ethambutol (ETH), pyrazynamide (PZA) and Rifampicin have been successfully loaded in polymeric core-shell nanoparticles of poly DL, lactic-co-glycolic acid (PLGA50:50), a biodegradable and biocompatible polymer, extensively used as a carrier.
  • Submicron solid particles of PLGA incorporating INH (or Eth or PZA or RIF) have been obtained by spray drying straightforward a typical double emulsion water-in-oil-in-water (W/O ⁇ /V).
  • chitosan a cationic biodegradable muco-adhesive polysaccharide
  • lactose monohydrate was used as spray drying-aid.
  • PVA was considered as the main stabiliser component of the double emulsion, while PEG was incorporated to increase the bio-circulation of the carrier.
  • Surfynol 104 PG-50 TM played a big role in decreasing the particle size towards the nanosize range while significantly narrowing the size distribution.
  • the frontline anti-tuberculosis drugs were purchased from Sigma.
  • Polyvinyl alcohol (PVA) (Mw: 13000-23000 and partially hydrolysed (87-89%) was also obtained from Sigma.
  • Stearic acid supplied by Merck Surfynol 104 PG-50 TM, a Gemini diol type surfactant, was supplied by Air Products.
  • Polyethylene glycol (PEG) (Mw 9000) was purchased from BASF Chemicals. Lactose monohydrate supplied by Merck, was used as an excipient.
  • the preparation of nanoparticles was achieved by the method based on the interfacial polymer precipitation from a double emulsion W/O ⁇ /V subsequent to the evaporation of the organic solvent.
  • the step of solvent evaporation and drying was combined in one step by applying the spray drying technique. Briefly, 50mg of INH was dissolved in a 2ml of phosphate buffer solution (pH7.4), which was added to a solution of 100mg of PLGA (50:50) dissolved in 8ml of the organic solvent (DCM or ethyl acetate). An optional 2ml of 0.2%(w/v) of stearic acid can also be dissolved in the same solvent (DCM or Ethyl acetate). A drop of Surfynol 104 PG-50 TM was intentionally added either to the PLGA oil phase or to the external aqueous phase containing PVA.
  • the mixture was subject to emulsification using the high speed homogeniser (Silverson L4R) at 5000 rpm for 3min to produce W/O emulsion.
  • This first emulsion obtained was then immediately poured into an aqueous phase volume of a known concentration of
  • a B ⁇ chi mini spray dryer model B-290 (B ⁇ chi Lab, Switzerland) with a standard nozzle (0.7 mm diameter) was used to produce the dry powders of the various formulations.
  • the conditions used are compiled in Table 1 : Table 1 Spray-drying process condition of B-290 B ⁇ chi Mini Spray Drier
  • the spray dryer was provided with a high performance cyclone, designed to get an excellent recovery of the material in the receiver vessel and reduce the adhesion of the product on the wall of the drying chamber.
  • Particle size and particle size distributions were measured by Dynamic Laser Scattering or Photon Correlation Spectroscopy using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd, UK). For each sample 3-5mg of spray dried powder were prepared by suspending the particles in filtered water (0.2 ⁇ m filter), vortexing and/or sonicating for 2 min if necessary. Each sample was measured in triplicate.
  • the zeta potential of the particles was measured using the Zetasizer Nano ZS (Malvern Instruments Ltd, UK). For that a sample of 3mg of the spray dried nanoparticles was suspended in 1-2ml of de-ionised water and then vortexed or sonicated before the measurement. Each measurement was taken in triplicate.
  • the amount of the hydrophilic drug Isoniazid that was entrapped in the particle powder after the nanoencapsulation process was measured in triplicate using a spectrophotometric method (UV-Vis, Thermo Spectronic Helios ⁇ ).
  • INH spray dried powders were assessed by reverse phase-high performance liquid chromatography-analysis (RP-HPLC) using Shimadzu machine supplied with Photodiode Array (PDA) detector.
  • RP-HPLC reverse phase-high performance liquid chromatography-analysis
  • PDA Photodiode Array
  • the yields of the powder for all the formulations investigated were in the range of 40- 70%.
  • the encapsulation efficiency of INH is approximating 60%.
  • DCM dichloromethane
  • EA ethyl acetate
  • E ⁇ A samples produced very irregular surface morphology compared to samples prepared with DCM. Particles from EA were highly dimpled and wrinkled before addition of lactose. Small doughnut-shaped particles were also observed
  • the size and the shape as well as surface morphology of nanoparticles were strongly affected by the composition of the phases. As the initial concentration of lactose was increased from 5 to 10% w/v, the particles shifted from highly wrinkled to nearly smooth spheres. The fraction of doughnut-shaped particles decreased sensibly, regardless the type of solvent used, as depicted by SEM pictures in Fig. 1C and D. However, much more surface smoothness has been observed with DCM in the scale of observation.
  • Nonionic surfactants based on acetylenic diol chemistry, represent a unique class of surfactants providing low surface tension and good de-foaming and surface wetting characteristics.
  • the acetylenic diol surfactants orient horizontally due to their molecular structure.
  • a compact molecule of this surfactant can migrate very rapidly to the interfacial region providing low values of the dynamic surface tension (DST). It was reported that for a Surfynol 104 PG-50 TM bulk concentration of 2.10 "6 mol. cm '3 , the DST dropped around 35 dynes.cm '1 . It is, indeed, this specific property of significantly decreasing the surface tension which motivated us to select it as a co-surfactant in our formulations.
  • PEG polyethylene glycol
  • PEG was introduced together with PVA in the external phase at an initial concentration of 0.5%w/v, dissolved in de-ionised water

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier, blending the drug to be delivered into one of the emulsion phases, doping either the oil-phase or the outer-water phase with a carbohydrate, and spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm, which nanoparticles are substantially spherical.

Description

NANOPARTICLE CARRIERS FOR DRUG ADMINISTRATION AND PROCESS FOR
PRODUCING SAME
Field of the Invention
The invention relates to nanoparticle carriers for oral administration of medically active compounds and/or other compounds.
Background to the Invention
The spray-drying technique has seen wide application in the preparation of pharmaceutical powders, mostly for pulmonary drug delivery, with specific characteristics such as particle size, density and shape. It is a well-established method for producing solid powder by atomising suspensions or solutions into droplets followed by a drying process in flowing hot air.
Although most often considered as a dehydration process, spray-drying can also be used as an encapsulation method where active substances are entrapped in a polymeric matrix or shell. It is reported that several colloidal systems such as emulsions or liposomes were successfully spray dried with preservation of their structure using drying-aid agents, particularly sugars such as lactose, sorbitol and trehalose.
One of the merits of the spray-drying technique is that it is a cost effective and quick drying process applicable to a broad range of pharmaceutical products and leading to the production of a free flowing powder, characterized by very low water content, preventing therefore the degradation of the active. This is meaningful for the development of long-term stable carriers, mostly when these carriers are in the range of nano scale, designed specifically for the delivery of active compounds at the site of interest.
Recently, it has been shown that the spray drying technique can produce nano scale solid particles and solid lipid nanoparticles loaded with active agents to be used as delivery systems for pulmonary airways. It is worthwhile to note that in most cases where this technique was applied to produce solid nanoparticles, it was, in fact, a drying process of nanocapsules obtained by other techniques. Thereafter the suspension of the nanoparticles was subjected to spray drying. This resulted often in the production of particles with very broad size range from nano to micron size, despite the presence of disaccharides as drying excipients in the formulation.
Recently, it was reported the spray drying of a liquid colloidal system in the drug delivery field, where a single emulsion (water-in-oil emulsion) containing DNA encapsulated in poly(lactic-co-glycolic acid (PLGA), was successfully spray dried. Another report was made on spray drying of a double emulsion (oil-in-water-in-oil or O/W/O), in the presence of lactose, aiming to preserve orange oil and in both cases the particles produced were in the micron size range.
A need has been identified for spherical nanoparticles having a narrow size distribution range, typically from 180 to 250 nm. Ideally such particles should have a substantially smooth surface and be free flowing. Summary of the Invention
The invention provides a process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by:
- preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier;
- blending the drug to be delivered into one or more of the emulsion phases;
- doping either the oil-phase or the outer-water phase with a carbohydrate; and - spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm.
The nanoparticles thus produced may be multifunctional nanoparticles.
The carbohydrate may be a saccharide.
The saccharide may be a disaccharide.
The disaccharide may be lactose, maltose, isomaltose, mannobiose, trehalose, cellobiose, or the like.
The saccharide may be combined with a cationic biodegradable muco-adhesive polysaccharide. The polysaccharide may be chitosan or derivatives thereof.
The oil-phase of the emulsion may be doped with a surfactant. The water-phase of the emulsion may be doped with surfactant.
The surfactant may be a nonionic surfactant.
The surfactant may be based on acetylenic diol chemistry.
The surfactant may be a polymeric nonionic surfactant.
The polymeric nonionic surfactant in the water-phase may be polyvinyl alcohol (PVA), partially hydrolysed.
The polymer may be in the oil-phase of the emulsion.
The polymer in the oil-phase may be PLGA (poly(lactic-co-glycolic acid)).
Both oil-phase and water-phase polymers may be present.
The drug may be added to the oil-phase. The drug may be a hydrophilic drug which is added to the internal water-phase.
The drug may be hydrophobic and may optionally be added to the oil phase.
The drug may be Rifampicin, Isoniazid, Ethambutol, or Pyrazynamide.
The outer water-phase of the emulsion may include polyethylene glycol (PEG).
The oil-phase may include stearic acid.
The nanoparticles thus formed may be substantially spherical.
The particle size distribution of the nanoparticles may be from 180 nm to 250 nm diameter.
The description of embodiments which follows should be interpreted broadly and not to limit the scope of the invention. SPECIFIC DESCRIPTION OF EMBODIMENTS OF THE INVENTION
1. Object of Experiment
For this experiment, anti-tuberculosis antibiotics including isoniazid (INH) ethambutol (ETH), pyrazynamide (PZA) and Rifampicin have been successfully loaded in polymeric core-shell nanoparticles of poly DL, lactic-co-glycolic acid (PLGA50:50), a biodegradable and biocompatible polymer, extensively used as a carrier. Submicron solid particles of PLGA incorporating INH (or Eth or PZA or RIF) have been obtained by spray drying straightforward a typical double emulsion water-in-oil-in-water (W/OΛ/V).
In the formulation, chitosan, a cationic biodegradable muco-adhesive polysaccharide, was employed as absorption enhancer while lactose monohydrate was used as spray drying-aid. PVA was considered as the main stabiliser component of the double emulsion, while PEG was incorporated to increase the bio-circulation of the carrier.
Surfynol 104 PG-50 ™, as a co-surfactant, played a big role in decreasing the particle size towards the nanosize range while significantly narrowing the size distribution.
2. Materials and Methods
2.1 Materials
The frontline anti-tuberculosis drugs were purchased from Sigma. Poly, DL, Lactic-co- Glycolic Acid, (PLGA) 50:50 (Mw: 45000-75000) and chitosan low Mw, 85% de- acetylated, were both supplied by Sigma. Polyvinyl alcohol (PVA) (Mw: 13000-23000 and partially hydrolysed (87-89%) was also obtained from Sigma. Stearic acid supplied by Merck, Surfynol 104 PG-50 ™, a Gemini diol type surfactant, was supplied by Air Products. Polyethylene glycol (PEG) (Mw 9000) was purchased from BASF Chemicals. Lactose monohydrate supplied by Merck, was used as an excipient.
Dichloromethane, ethyl acetate and acetonitrile, analytical and HPLC grades were also supplied by Merck.
2.2 Methods
2.2.1 Formulation
The preparation of nanoparticles was achieved by the method based on the interfacial polymer precipitation from a double emulsion W/OΛ/V subsequent to the evaporation of the organic solvent. In this invention, the step of solvent evaporation and drying was combined in one step by applying the spray drying technique. Briefly, 50mg of INH was dissolved in a 2ml of phosphate buffer solution (pH7.4), which was added to a solution of 100mg of PLGA (50:50) dissolved in 8ml of the organic solvent (DCM or ethyl acetate). An optional 2ml of 0.2%(w/v) of stearic acid can also be dissolved in the same solvent (DCM or Ethyl acetate). A drop of Surfynol 104 PG-50 ™ was intentionally added either to the PLGA oil phase or to the external aqueous phase containing PVA.
The mixture was subject to emulsification using the high speed homogeniser (Silverson L4R) at 5000 rpm for 3min to produce W/O emulsion. This first emulsion obtained was then immediately poured into an aqueous phase volume of a known concentration of
PVA (1 or 2% w/v), PEG 0.5% w/v, chitosan and lactose aqueous solution in a defined volume ratio, and emulsified to form the double emulsion W/C7W again by means of the high speed homogenizer (Silverson L4R) at 8000rpm for 5min. The final emulsion obtained was directly fed through a spray dryer to produce nanoparticles using the conditions specified in Table 1.
Spray drying
A Bϋchi mini spray dryer model B-290 (Bϋchi Lab, Switzerland) with a standard nozzle (0.7 mm diameter) was used to produce the dry powders of the various formulations. The conditions used are compiled in Table 1 : Table 1 Spray-drying process condition of B-290 Bϋchi Mini Spray Drier
Condition Parameter
Atomizing air volumetric flow rate 800 NL/h
Feeding rate 1.0 mL/min
Aspirator rate 100%
Inlet (outlet) temperature 90 -1100C (53-63°C)
Pressure for atomisation 6-7 bars
The spray dryer was provided with a high performance cyclone, designed to get an excellent recovery of the material in the receiver vessel and reduce the adhesion of the product on the wall of the drying chamber.
2.2.2 Particle size and size distribution
Particle size and particle size distributions were measured by Dynamic Laser Scattering or Photon Correlation Spectroscopy using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd, UK). For each sample 3-5mg of spray dried powder were prepared by suspending the particles in filtered water (0.2μm filter), vortexing and/or sonicating for 2 min if necessary. Each sample was measured in triplicate.
2.2.3 Zeta potential
The zeta potential of the particles was measured using the Zetasizer Nano ZS (Malvern Instruments Ltd, UK). For that a sample of 3mg of the spray dried nanoparticles was suspended in 1-2ml of de-ionised water and then vortexed or sonicated before the measurement. Each measurement was taken in triplicate.
2.2.4 Scanning electron microscope
Surface morphology of spray dried nanoparticles was visualized by scanning electron microscopy (LEO 1525 Field Emission SEM.). A small amount of nanoparticle powder was mounted on a brass stub using a double-sided adhesive tape and vacuum-coated with a thin layer of gold by sputtering.
2.2.5 Drug incorporation
The amount of the hydrophilic drug Isoniazid that was entrapped in the particle powder after the nanoencapsulation process was measured in triplicate using a spectrophotometric method (UV-Vis, Thermo Spectronic Heliosα). The encapsulation efficiency of INH in nanoparticles was determined as the mass ratio of the entrapped INH to the theoretical amount of INH used in the preparation. For that, 50mg of precipitated particles were re-suspended in 20 ml of deionised water, centrifuged (10 000rpm/10C/5min) to remove the un-encapsulated drug and the supernatant was subject to UV-Vis Spectrophotometer, read at λ= 262nm for INH assessment. The encapsulated amount of INH was determined by subtracting INH in the supernatant from total initial INH amount.
INH stability assessment using HPLC
The stability of INH spray dried powders was assessed by reverse phase-high performance liquid chromatography-analysis (RP-HPLC) using Shimadzu machine supplied with Photodiode Array (PDA) detector.
The following characteristics were applied: a Column Phenomenex [(C18 (5μm); (250 x 4.6mm ID)], a mobile phase of 5% (v/v) acetonitrile with 95% (v/v) buffer NaH2PO4 (pH 6.8), at a flow rate of 1 ml/min and at a temperature of 300C. The detection was performed using PDA at λ= 259nm, on a total injection volume of 20//I.
3. Results and Discussion
All spray drying runs produced nanoparticles with a size ranging from approximately 220 to 800nm. The concentration of the liquid feed did not show any influence on the size of particles as illustrated with samples where the PVA concentration was changed from 1 to 2%. Only the addition of lactose and Surfynol 104 PG-50 ™ demonstrated a significant impact on the size and the morphology of nanoparticles. Interestingly, just one drop of the Gemini surfactant added to the oil phase, drastically reduced the size and the size distribution of the product, irrespective of either the type of organic solvent or the concentration of PVA. During all the sets of experiments beside the temperature, all other parameters of the spray dryer were kept constant. The mass ratio PLGA: INH (2:1) was also unchanged. The addition of lactose improved significantly the shape of nanoparticles. This effect was pronounced when dichloromethane was used as organic solvent.
The yields of the powder for all the formulations investigated were in the range of 40- 70%.
The residual water content of selected samples, determined by thermal analysis, showed a very low level of moisture (-3%).
Results obtained from HPLC indicated the degradation of INH, possibly due to interaction with lactose. This challenge was overcome by capping the functional groups of lactose with chitosan, prior to their incorporation in the formulation.
The encapsulation efficiency of INH is approximating 60%.
3.1 Effect of solvent on particles size and morphology
The most commonly used organic solvents in double emulsion technique are dichloromethane (DCM) and ethyl acetate (EA).
Thus, we decided to monitor the size and the morphology of nanoparticles by varying the organic solvent. In all cases, when ethyl acetate was used as organic solvent, the first emulsion obtained presented an aspect of a transient stable emulsion, this observation being based on the less milky appearance of the emulsion when compared to the one obtained with DCM.
EΞA samples produced very irregular surface morphology compared to samples prepared with DCM. Particles from EA were highly dimpled and wrinkled before addition of lactose. Small doughnut-shaped particles were also observed
3.2 Effect of additives
3.2.1 Effect of lactose on particle size and morphology
The size and the shape as well as surface morphology of nanoparticles were strongly affected by the composition of the phases. As the initial concentration of lactose was increased from 5 to 10% w/v, the particles shifted from highly wrinkled to nearly smooth spheres. The fraction of doughnut-shaped particles decreased sensibly, regardless the type of solvent used, as depicted by SEM pictures in Fig. 1C and D. However, much more surface smoothness has been observed with DCM in the scale of observation.
The particle size decreased as we compared with formulations without addition of lactose, regardless of the type of organic solvent used. The decay was much more pronounced in case of DCM as illustrated by results presented in Figure 2: the z- average size of particles dropped from more than 1200 nm to 450nm, when lactose was added to the formulation. Zeta potentials were in the positive range because of the presence of chitosan in the formulation. Its initial concentration was varied between 0.05, 0.1 and 0.3% (w/v) and the optimisation of the formulation was done with chitosan 0.3%, which resulted in a high positive zeta potential ~ +45mV.
3.2.2 Effect of Surfynol 104 PG-50 ™ on particle size and yield
Nonionic surfactants, based on acetylenic diol chemistry, represent a unique class of surfactants providing low surface tension and good de-foaming and surface wetting characteristics.
Contrary to most surfactants that orient vertically at the water/air interface, the acetylenic diol surfactants orient horizontally due to their molecular structure. A compact molecule of this surfactant can migrate very rapidly to the interfacial region providing low values of the dynamic surface tension (DST). It was reported that for a Surfynol 104 PG-50 ™ bulk concentration of 2.10"6mol. cm'3, the DST dropped around 35 dynes.cm'1. It is, indeed, this specific property of significantly decreasing the surface tension which motivated us to select it as a co-surfactant in our formulations.
Surfynol 104 PG-50 ™ was added to the internal oil phase before introduction of the drug aqueous phase. The product obtained was characterised by a very small particle size about 230nm and the experimental results were reproducible.
The size distribution was equally very narrow (PolyDispersity Index (PDI) ~ 0.1) due presumably to the capability of Surfynol 104 PG-50 ™to prevent aggregation. 3.2.3 Effect of PEG and Stearic acid on morphology
It is well established that polyethylene glycol (PEG) is extensively used in drug delivery strategies in order to generate entities which are less easily recognised by macrophages and hence exhibit prolonged circulation times in the blood. On the biological level, coating nanoparticles with PEG sterically hinders interactions of blood components with their surface and reduces the binding of plasma proteins with PEGylated nanoparticles. This prevents drug carrier interaction with opsonins and slows down their capture by the reticulo-endothelial systems (RES).
PEG was introduced together with PVA in the external phase at an initial concentration of 0.5%w/v, dissolved in de-ionised water
As we combine the presence of 5ml of PEG (0.5% w/v) in aqueous external phase and 2ml of stearic acid (0.2%w/v) added into the oily phase of the polymer, as a co- surfactant together with Surfynol 104 PG-50 ™, a significant improvement of the surface morphology was observed, as depicted in Fig. 3. The reading on Zetasizer provided smaller particles size of about 270nm with a very narrow distribution (PDI -0.2).

Claims

Claims
1. A process for the production of nanoparticle carriers for drug delivery, said nanoparticles being produced by:
- preparing a double emulsion of water-oil-water including one or more polymer which forms the basis of the nanoparticle carrier;
- blending the drug to be delivered into one of the emulsion phases;
- doping either the oil-phase or the outer-water phase with a carbohydrate; and
- spray drying the emulsion to form nanoparticles of a narrow particle size distribution of 100 nm to 1000 nm.
2. A process as claimed in claim 1, wherein the nanoparticles thus produced are multifunctional nanoparticles.
3. A process as claimed in claim 1 or claim 2, wherein the carbohydrate is a saccharide.
4. A process as claimed in claim 3, wherein the saccharide is a disaccharide.
5. A process as claimed in claim 4, wherein the disaccharide is selected from the group including lactose, maltose, isomaltose, mannobiose, trehalose, and cellobiose.
6. A process as claimed in any one of claims 3 to 5, wherein the saccharide is combined with a cationic biodegradable muco-adhesive polysaccharide.
7. A process as claimed in claim 6, wherein the polysaccharide is chitosan and/or derivatives thereof.
8. A process as claimed in any one of the preceding claims, wherein the oil-phase of the emulsion is doped with a surfactant.
9. A process as claimed in any one of the preceding claims, wherein the water- phase of the emulsion is doped with surfactant.
10. A process as claimed in any one of the preceding claims, wherein the surfactant is a non-ionic surfactant.
11. A process as claimed in claim 10, wherein the surfactant is based on acetylenic diol chemistry.
12. A process as claimed in claim 10, wherein the surfactant is a polymeric non-ionic surfactant.
13. A process as claimed in claim 12, wherein the polymeric non-ionic surfactant in the water-phase is PVA.
14. A process as claimed in any one of the preceding claims, wherein there is a polymer in the oil-phase of the emulsion.
15. A process as claimed in claim 14, wherein the polymer in the oil-phase is PLGA (poly(lactic-co-glycolic acid).
16. A process as claimed in any one of the preceding claims, wherein polymers are present in both the oil-phase and the water-phase.
17. A process as claimed in any one of the preceding claims, wherein the drug is added to the oil-phase.
18. A process as claimed in claim 17, wherein the drug is a hydrophilic drug which is added to the internal water-phase.
19. A process as claimed in claim 17 or claim 18, wherein the drug is hydrophobic.
20. A process as claimed in any one of the preceding claims, wherein the drug is selected from Rifampicin, Isoniazid, Ethambutol, or Pyrazynamide.
21. A process as claimed in any one of the preceding claims, wherein the outer water-phase of the emulsion includes polyethylene glycol (PEG).
22.A process as claimed in any one of the preceding claims, wherein the oil-phase includes stearic acid.
23.A process as claimed in any one of the preceding claims, wherein the nanoparticles thus formed are substantially spherical.
24.A process as claimed in claim 23, wherein the particle size distribution of the nanoparticles is from 180 nm to 250 nm diameter.
25.A process as claimed in claim 1, substantially as herein described.
26.A new process substantially as herein described.
PCT/ZA2008/000012 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same Ceased WO2009105792A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP08733215A EP2249817B8 (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
AU2008351331A AU2008351331B2 (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
AT08733215T ATE537817T1 (en) 2008-02-18 2008-02-18 NANOPARTICLE CARRIER FOR DELIVERY OF MEDICINAL PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF
CA2714429A CA2714429C (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
ES201090058A ES2397016B1 (en) 2008-02-18 2008-02-18 TRANSPORTERS OF NANOPARTICLES FOR DRUG ADMINISTRATION AND PROCEDURE TO PRODUCE THE SAME.
CN2008801270301A CN101951895B (en) 2008-02-18 2008-02-18 Nanoparticle carrier for drug administration and preparation method thereof
MX2010008902A MX2010008902A (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same.
AP2010005389A AP2966A (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
JP2010547882A JP5575667B2 (en) 2008-02-18 2008-02-18 Nanoparticle carrier for drug administration and method for producing the same
HK10112296.4A HK1145973B (en) 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
PCT/ZA2008/000012 WO2009105792A1 (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
DE112008003727T DE112008003727T5 (en) 2008-02-18 2008-02-18 Nanoparticle carrier for drug delivery and process for its preparation
GB1013546.5A GB2469965B (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same
US12/858,074 US8518450B2 (en) 2008-02-18 2010-08-17 Nanoparticle carriers for drug administration and process for producing same
ZA2010/06639A ZA201006639B (en) 2008-02-18 2010-09-16 Nanoparticle carriers for drug administration and process for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ZA2008/000012 WO2009105792A1 (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/858,074 Continuation-In-Part US8518450B2 (en) 2008-02-18 2010-08-17 Nanoparticle carriers for drug administration and process for producing same

Publications (1)

Publication Number Publication Date
WO2009105792A1 true WO2009105792A1 (en) 2009-08-27

Family

ID=39790304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2008/000012 Ceased WO2009105792A1 (en) 2008-02-18 2008-02-18 Nanoparticle carriers for drug administration and process for producing same

Country Status (14)

Country Link
US (1) US8518450B2 (en)
EP (1) EP2249817B8 (en)
JP (1) JP5575667B2 (en)
CN (1) CN101951895B (en)
AP (1) AP2966A (en)
AT (1) ATE537817T1 (en)
AU (1) AU2008351331B2 (en)
CA (1) CA2714429C (en)
DE (1) DE112008003727T5 (en)
ES (1) ES2397016B1 (en)
GB (1) GB2469965B (en)
MX (1) MX2010008902A (en)
WO (1) WO2009105792A1 (en)
ZA (1) ZA201006639B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126985A (en) * 2011-11-29 2013-06-05 财团法人交大思源基金会 Double-emulsion core-shell nano structure and preparation method thereof
US20150000846A1 (en) * 2012-02-07 2015-01-01 Centre National De La Recherche Scientifique Preparation of nanoparticles by flash evaporation
WO2020036501A1 (en) * 2018-08-17 2020-02-20 Smela Krysztof Multicompartment system of nanocapsule-in-nanocapsule type, for encapsulation of a lipophilic and hydrophilic compound, and the related production method
WO2020229971A1 (en) * 2019-05-14 2020-11-19 Council For Scientific And Industrial Research Polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds
CN116256455A (en) * 2023-03-20 2023-06-13 东营天东制药有限公司 Method for identifying bovine pulmonary heparin doping content in porcine intestinal mucosa derived heparin

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815294B2 (en) * 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9283298B2 (en) 2013-09-25 2016-03-15 Clemson University Compliant surgical adhesive
US9850521B2 (en) * 2014-08-01 2017-12-26 Agilent Technologies, Inc. In vitro assay buffer for Cas9
JP2018523702A (en) * 2015-08-17 2018-08-23 フォスフォレックス，インコーポレイテッド Degradable polymer ultra-small nanoparticles
US20190105282A1 (en) * 2016-03-23 2019-04-11 Che-Ming Jack Hu Thin-shell polymeric nanoparticles and uses thereof
CN109628547B (en) * 2018-12-14 2022-02-25 陕西师范大学 A kind of modified magnetic bead, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099262A1 (en) * 2002-05-28 2003-12-04 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously
EP1595549A1 (en) * 2003-02-19 2005-11-16 Takeda Pharmaceutical Company Limited Dispersant for sustained release preparations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
IT1296914B1 (en) * 1997-12-01 1999-08-03 Maria Rosa Gasco PHARMACEUTICAL COMPOSITION INCLUDING MICROPARTICLES SUITABLE FOR TRANSMUCOSAL PASSAGE AND OVERCOMING THE BARRIER
US7354886B2 (en) * 1999-07-29 2008-04-08 Baker Hughes Incorporated Pumpable multiple phase compositions for controlled release applications downhole
JP4751556B2 (en) * 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド Nanocapsule encapsulation system and method
EP1328612B1 (en) * 2000-10-27 2007-04-25 Genencor International, Inc. Particle with substituted polyvinyl alcohol coating
JP2003175092A (en) * 2001-07-10 2003-06-24 Canon Inc Granules containing polyhydroxyalkanoate, process for producing the same, and uses thereof
KR100521526B1 (en) * 2001-07-10 2005-10-13 캐논 가부시끼가이샤 Particulate construct comprising polyhydroxyalkanoate and method for producing it
ITTO20020452A1 (en) * 2002-05-29 2003-12-01 Vhit Spa PNEUMATIC VALVE FOR LIMITING THE LEVEL OF DEPRESSION AND BRAKING SYSTEM WHICH INVOLVES THIS VALVE.
ES2420479T3 (en) * 2006-08-31 2013-08-23 Sk Chemicals, Co., Ltd. Procedure for the production of microspheres loaded with drugs and microspheres loaded with drugs produced therewith
EP2061433B1 (en) * 2006-09-08 2011-02-16 Johns Hopkins University Compositions for enhancing transport through mucus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099262A1 (en) * 2002-05-28 2003-12-04 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously
EP1595549A1 (en) * 2003-02-19 2005-11-16 Takeda Pharmaceutical Company Limited Dispersant for sustained release preparations

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103126985A (en) * 2011-11-29 2013-06-05 财团法人交大思源基金会 Double-emulsion core-shell nano structure and preparation method thereof
CN103126985B (en) * 2011-11-29 2015-01-21 财团法人交大思源基金会 Double-emulsion core-shell nano structure and preparation method thereof
US20150000846A1 (en) * 2012-02-07 2015-01-01 Centre National De La Recherche Scientifique Preparation of nanoparticles by flash evaporation
US10722813B2 (en) * 2012-02-07 2020-07-28 Isl—Institut Franco-Allemand De Recherches De Saint-Louis Preparation of nanoparticles by flash evaporation
WO2020036501A1 (en) * 2018-08-17 2020-02-20 Smela Krysztof Multicompartment system of nanocapsule-in-nanocapsule type, for encapsulation of a lipophilic and hydrophilic compound, and the related production method
WO2020229971A1 (en) * 2019-05-14 2020-11-19 Council For Scientific And Industrial Research Polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds
CN113924121A (en) * 2019-05-14 2022-01-11 科学和工业研究委员会 Polymer-lipid nanocomposites for enhanced water solubility and absorption of hydrophobic active compounds
US20220233455A1 (en) * 2019-05-14 2022-07-28 Council For Scientific And Industrial Research Polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds
CN113924121B (en) * 2019-05-14 2025-12-09 科学和工业研究委员会 Polymer-lipid nanocomposites for enhancing water dissolution and absorption of hydrophobic active compounds
CN116256455A (en) * 2023-03-20 2023-06-13 东营天东制药有限公司 Method for identifying bovine pulmonary heparin doping content in porcine intestinal mucosa derived heparin

Also Published As

Publication number Publication date
CA2714429A1 (en) 2009-08-27
AP2010005389A0 (en) 2010-10-31
EP2249817A1 (en) 2010-11-17
GB2469965A (en) 2010-11-03
AP2966A (en) 2014-09-30
US8518450B2 (en) 2013-08-27
CN101951895B (en) 2013-11-06
ATE537817T1 (en) 2012-01-15
MX2010008902A (en) 2011-03-02
EP2249817B8 (en) 2012-03-21
HK1145973A1 (en) 2011-05-13
EP2249817B1 (en) 2011-12-21
GB2469965B (en) 2012-06-20
JP5575667B2 (en) 2014-08-20
CN101951895A (en) 2011-01-19
JP2011512418A (en) 2011-04-21
AU2008351331A1 (en) 2009-08-27
ES2397016A1 (en) 2013-03-04
ES2397016B1 (en) 2014-01-17
US20110033550A1 (en) 2011-02-10
GB201013546D0 (en) 2010-09-29
GB2469965A8 (en) 2010-11-24
DE112008003727T5 (en) 2011-04-21
ZA201006639B (en) 2012-03-28
AU2008351331B2 (en) 2014-07-17
CA2714429C (en) 2015-04-28

Similar Documents

Publication Publication Date Title
EP2249817B1 (en) Nanoparticle carriers for drug administration and process for producing same
Mehandole et al. Core–shell type lipidic and polymeric nanocapsules: the transformative multifaceted delivery systems
Sonaje et al. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats
Chaisri et al. Preparation and characterization of cephalexin loaded PLGA microspheres
Fang et al. Nanostructured lipid carriers (NLCs) for drug delivery and targeting
EP1023050B1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
Liu et al. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method
Ueda et al. Optimization of the preparation of loperamide-loaded poly (L-lactide) nanoparticles by high pressure emulsification-solvent evaporation
Corrias et al. New methods for lipid nanoparticles preparation
CN107683133A (en) Mix the drug delivery composition of particulate comprising polvmeric lipid
Mu et al. Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug
Mok et al. Direct plasmid DNA encapsulation within PLGA nanospheres by single oil-in-water emulsion method
de Faria et al. Preparation and characterization of poly (D, L‐lactide)(PLA) and poly (D, L‐lactide)‐poly (ethylene glycol)(PLA‐PEG) nanocapsules containing antitumoral agent methotrexate
Rahman et al. Systematic development of sertraline loaded solid lipid nanoparticle (SLN) by emulsification-ultrasonication method and pharmacokinetic study in Sprague-Dawley rats
Luan et al. Mannosamine-engineered nanoparticles for precision rifapentine delivery to macrophages: Advancing targeted therapy against Mycobacterium tuberculosis
EP3266450A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
Sulaiman Khil et al. Several applications of solid lipid nanoparticles in drug delivery
Cillari et al. Hybrid Poly (ε-caprolactone)–Carbon Dot Nanoparticles as Self-Tracking Theranostic Tools for Precise Docetaxel Delivery
Nirbhavane et al. Role of biodegradable polymeric nanoparticles for the treatment of tuberculosis
Selvaraj et al. FORMULATION AND INVITRO EVALUATION OF TRANDOLAPRIL SOLID LIPID COMPACT NANOPARTICLE
Okonogi et al. Preparation of cephalexin microspheres by double emulsion technique
AU2002300723B2 (en) Novel Formulations of Pharmacological Agents, Methods for the Preparation Thereof and Methods for the Use Thereof
Kawashima Development of a PLGA-Nanosphere DDS Prepared by Spherical Crystallization with a Polymer
Chandratre Multifunctional Nanoparticles for Cancer Therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P201090058

Country of ref document: ES

Ref document number: 200880127030.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733215

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008351331

Country of ref document: AU

Ref document number: 2714429

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4999/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 1013546

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20080210

WWE Wipo information: entry into national phase

Ref document number: 1013546.5

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/008902

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010547882

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2008351331

Country of ref document: AU

Date of ref document: 20080218

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008733215

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10201000001319

Country of ref document: CH

WWE Wipo information: entry into national phase

Ref document number: 2010138291

Country of ref document: RU

RET De translation (de og part 6b)

Ref document number: 112008003727

Country of ref document: DE

Date of ref document: 20110421

Kind code of ref document: P